Retatrutide Research: Advancements in Triple Agonism

Research and Science

Retatrutide (LY3437943): Advancing Triple Agonist Research

Retatrutide is a next-generation synthetic peptide designed as a triple receptor agonist. It simultaneously targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon (GCG) receptors. This unique multi-pathway mechanism distinguishes it from earlier single-agonist and dual-agonist compounds, offering researchers a powerful tool for studying metabolic regulation, energy expenditure, appetite control, and body composition.

As a licensed pharmaceutical company at the forefront of Retatrutide discovery, we offer high-purity Retatrutide research peptide specifically developed for laboratory and preclinical scientific studies worldwide. Explore our full range on the Products / Shop Page.

Mechanism of Action

Retatrutide’s triple agonism works synergistically:

GLP-1 Receptor Activation: Enhances glucose-dependent insulin secretion, slows gastric emptying, and promotes satiety.
GIP Receptor Activation: Improves insulin sensitivity and supports lipid metabolism.
Glucagon Receptor Activation: Increases energy expenditure and promotes fat oxidation (thermogenesis).

This balanced activation is currently being investigated in advanced metabolic research. For more details on proper handling and administration in laboratory settings, please refer to our Prescribing Information page.

Key Research Findings

Preclinical and clinical studies of Retatrutide have demonstrated promising results, including significant weight reduction, improved metabolic parameters, and reductions in liver fat. These findings position Retatrutide as one of the most advanced candidates in obesity and metabolic disease research.

Retatrutide vs Tirzepatide vs Semaglutide

Aspect	Semaglutide	Tirzepatide	Retatrutide
Receptors Targeted	GLP-1 only	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Weight Loss (Trials)	~15–20%	~20–22%	Up to 24–28%+
Energy Expenditure	Moderate	Enhanced	Highest (glucagon effect)
Development Stage	Approved	Approved	Investigational (Phase 3)

Read more detailed scientific comparisons on this Research and Science page.

Dosing Guidelines for Research

Accurate dosing is critical for reproducible results. Our Retatrutide injectable pens and multi-dose vials (10mg to 50mg) are designed to support precise laboratory protocols. Researchers should follow established scientific methodologies. Full guidance is available on our Prescribing Information page.

Important Note: All products are sold strictly for research and laboratory use only and are not intended for human consumption. Please review our Medical Disclaimer.